Advertisement
U.S. markets open in 4 hours 26 minutes
S&P Futures
4,582.00 +5.25 (+0.11%) Dow Futures
36,083.00 +73.00 (+0.20%) Nasdaq Futures
15,987.25 +1.75 (+0.01%) Russell 2000 Futures
1,820.50 +8.30 (+0.46%) Crude Oil
75.79 -0.17 (-0.22%) Gold
2,067.50 +10.30 (+0.50%)
At close: 04:00PM EST
Pre-Market:
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 158.85 |
| Open | 159.25 |
| Bid | 0.00 x 800 |
| Ask | 166.45 x 900 |
| Day's Range | 156.67 - 160.16 |
| 52 Week Range | 132.24 - 243.52 |
| Volume | |
| Avg. Volume | 1,605,891 |
| Market Cap | 23.201B |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | 25.65 |
| EPS (TTM) | 6.15 |
| Earnings Date | Jan 24, 2024 - Jan 29, 2024 |
| Forward Dividend & Yield | 1.92 (1.22%) |
| Ex-Dividend Date | Nov 08, 2023 |
| 1y Target Est | 178.38 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-4% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for RMD
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- ResMed Inc.RMD: Raising target price to $125.00RESMED INC has an Investment Rating of SELL; a target price of $125.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.RatingFair ValueEconomic Moat2 days agoArgus Research
GuruFocus.comInsider Sell: CFO Brett Sandercock Sells 3,000 Shares of ResMed Inc (RMD)
ResMed Inc (NYSE:RMD), a global leader in the development, manufacturing, and marketing of innovative medical products for the treatment and management of respiratory disorders, with a focus on sleep-disordered breathing, has recently witnessed a significant insider sell by its Chief Financial Officer (CFO), Brett Sandercock.
Simply Wall St.Investors Shouldn't Overlook The Favourable Returns On Capital At ResMed (NYSE:RMD)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
MedTech DiveResmed overhauls C-suite, creating 3 posts and parting ways with 2 execs
The company recently laid off 5% of its staff and stopped certain projects to lower operating costs.
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.